DiaMedica Therapeutics Inc.
NASDAQ:DMACBiotechnology
-$0.01 today
- Market cap
- $463.49M
- Beta
- 1.00
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.65
Volume 0.21M
Average 0.19M
DMAC Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
DiaMedica Therapeutics Inc.NASDAQ: DMAC
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation dips below year-ago levels
Q1 FY2026 stock-based compensation of $822K fell 5.2% year over year, behind the +13.0% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 31.0% from the prior quarter. Over 3 fiscal years it compounded at +36.8% a year.
Context
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -5.2% toward the trailing-twelve-month pace of +13.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 3.85M USD
- Year-over-year change
- +84.5%
- 4-year CAGR
- +25.3%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.85M | +84.5% |
| FY2024 | 2024-12-31 | 2.09M | +23.9% |
| FY2023 | 2023-12-31 | 1.68M | +12.1% |
| FY2022 | 2022-12-31 | 1.5M | -3.6% |
| FY2021 | 2021-12-31 | 1.56M | — |
Stock-Based Compensation vs competitors
How DMAC compares with its peers on the latest reported figures
- DMAC's LTM Mar 2026 stock-based compensation of $2.79M is the 6th largest of the 7 companies compared; the peer median is $15.09M.
- Its year-over-year change of +13.0% is the 5th highest of 7, against a peer median of +41.2%.
- Over three fiscal years its annual growth of +36.8% compares with a peer median of +17.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $69.95M | +39.2% | -0.1% | 1941.0% | |
| LTM Mar 2026 | $20.28M | +92.0% | +34.5% | 101.4% | |
| LTM Mar 2026 | $17.19M | -38.8% | -30.2% | 1933.5% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $13M | +43.2% | +66.3% | 126.0% |
| LTM Mar 2026 | $12.76M | +67.9% | -14.2% | 5.5% | |
| LTM Mar 2026 | $2.79M | +13.0% | +36.8% | — | |
| LTM Mar 2026 | $2.1M | -12.1% | +36.1% | — | |
| Peer median (excluding DMAC) | $15.09M | +41.2% | +17.2% | 126.0% | |
Competitors are the stored peer set for DMAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (13.59M) | (13.68M) | (19.38M) | (24.44M) | (32.77M) |
| Depreciation & Amortization | 24K | 25K | 30K | 39K | (899K) |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.56M | 1.5M | 1.68M | 2.09M | 3.85M |
| Change in Working Capital | (461K) | 585K | 93K | 1.51M | 675K |
| Accounts Receivables | 210K | 48K | (287K) | 133K | (22K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (590K) | 225K | 192K | 14K | 535K |
| Other Working Capital | (81K) | 312K | 188K | 1.37M | 162K |
| Other Non-Cash Items | 219K | 53K | (1.15M) | (1.27M) | 82K |
| Operating Cash Flow | (12.25M) | (11.51M) | (18.73M) | (22.08M) | (29.06M) |
| Capital Expenditures | (22K) | (81K) | (24K) | (25K) | (40K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (69.81M) | (45.68M) | (69.41M) | (50.41M) | (59.28M) |
| Sales of Investments | 49.3M | 57.3M | 51.14M | 59M | 57.13M |
| Other Investing Activities | 2K | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (20.54M) | 11.54M | (18.3M) | 8.56M | (2.19M) |
| Debt Repayment | (6K) | (6K) | (6K) | (9K) | (10K) |
| Common Stock Issued | 29.85M | 0 | 36.85M | 11.75M | 44.29M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 244K | 0 | 0 | 256K | (400K) |
| Financing Cash Flow | 30.09M | (6K) | 36.84M | 11.99M | 43.88M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (2.7M) | 21K | (185K) | (1.52M) | 12.62M |
| Free Cash Flow | (12.27M) | (11.59M) | (18.75M) | (22.1M) | (29.1M) |
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
Intrinsic Alpha fair value
Locked
Current Price
$8.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.